

HeraMED completes AU\$2.58 million Private Placement

- HeraMED has successfully raised \$2.58 million (before costs) in a Placement to sophisticated and professional investors
- The raising was priced at \$0.07 per share, a 6.67% discount to HeraMED's last closing price before trading halt
- For each new share issued there is an attaching option on a 1-for-2 basis, with an exercise price of \$0.12 per share and a 3-year term from the date of issue
- The proceeds of the Placement will be used to accelerate commercialisation of HeraCARE in Australia and the US, inventory, continuing platform development and integrations as well as working capital purposes

HeraMED Limited (ASX:HMD) ("**HeraMED**" or the "**Company**"), a medical data and technology company leading the digital transformation of maternity care, is pleased to announce a successful private Placement (the "**Placement**") of \$2.58 million (before costs) to sophisticated and professional investors.

HeraMED has raised \$2.58 million in new capital via the issue of ~36.86 million new ordinary shares, priced at \$0.07 per share. The issue price is at a 6.67% discount to HeraMED's last closing price before it went into trading halt pre-market on Monday 10th July. For each new share issued there will be an attaching unlisted option on a 1-for-2 basis. The attaching options will have a strike price of \$0.12 per share (which represents a circa 70% premium to the Placement price) and an expiry date 3 years from the date of issue.

The issue of new shares and options will be issued via the placement capacity available to HeraMED under ASX Listing Rule 7.1 (18,428,572 options and 12,969,985 shares) and 7.1A (23,887,158 shares). Clarity Capital Advisors Pty Ltd acted as Lead Manager to the issue.

The proceeds of the Placement will fund:

- execution of HeraCARE commercialisation strategy in key markets of US and Australia;
- inventory build;
- continued refinement of the HeraCARE platform as well as integration work into new customers; and
- costs of the offer.

HeraMED Executive Chairman, Dr Ron Weinberger: “We are pleased with the support offered to us through this Placement. It is now encumbered on the Company to go and deliver. I absolutely believe we have the gold standard technology that will transform remote patient monitoring in maternity which is supported by the Company’s accelerating pipeline of commercial opportunities across multiple customer verticals and geographies. We now need to execute.

Through the existing deployments, pilots and trials of HeraCARE we are building a compelling evidence base showing HeraCARE provides 3 deliverables;

1. improved care outcomes;
2. increase productivity within the hospital or clinic; and
3. an ability to drive revenue growth for the healthcare provider through reimbursement.

In both the US and Australia, we need to capitalise on the unique opportunity to establish HeraCARE as the standard of care for remote maternity monitoring. We are in an enviable position because our technology has relevance across several verticals which reduces risk and should support a rapid rollout.

Keith and Anoushka are building really robust pipelines in both the US and Australia and I am confident we will deliver further pilots and deployments of HeraCARE in both markets in the near term.”

-ENDS-

This announcement has been authorised by the Board of HeraMED Limited.

HeraMED Limited
Executive Chairman
Dr Ron Weinberger
E: ron@hera-med.com

Company Secretary
Jonathan Hart
E: Jonathan@hera-med.com

Investor Relations
Tim Chapman
T: +61 419 897 062
E: tchapman@claritycap.com.au

About HeraMED Limited (ASX:HMD):

HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, and big data.

About HeraCARE:

The Company’s proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.